| Prev Close | 29.04 |
| Day Low/High | 28.72 / 29.37 |
| 52 Wk Low/High | 17.55 / 41.57 |
| Avg Volume | 722.00K |
| Exchange | NASDAQ |
| Shares Outstanding | 69.85M |
| Market Cap | 2.03B |
| EPS | 0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
How do you get a stock moving? Jim Cramer says the answer is to invest in technology.
Indicated as a Companion Diagnostic for Lynparza® (olaparib) for Use in Patients With Metastatic Inoperable or Recurrent Breast Cancer
Levi & Korsinsky announces it has commenced an investigation of Myriad Genetics, Inc.
Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Myriad Genetics, Inc.
The law firm of Kirby McInerney LLP announced today an investigation on behalf of Myriad Genetics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Myriad Genetics, Inc.
Position Statement Also Supports Access to Hereditary Cancer Testing for Prostate Cancer
Myriad Teams Up with Fight Colorectal Cancer to Support the #StrongArmSelfie Social Media Campaign throughout March
Prolaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 Prostate Cancer Patients per Year
Large National Payer Expands Coverage Policy to Include EndoPredict for Guiding Extended Hormone Therapy for Patients with ER+ Breast Cancer
Results from a Large 1,100 Patient Study Will Be Presented at the 2018 Genitourinary Cancer Symposium
Jim Cramer focuses on S&P Global, Myriad Genetics, ProLogis, Emerson Electric, Ball Corp. and more.
Jim Cramer says being a realistic investor doesn't mean being negative, especially when solid reality supports optimism.
Recommends all Metastatic Prostate Cancer Patients Receive Genetic Testing
First Phase III PARP Inhibitor Clinical Trial to Use myChoice® HRD Plus as a Potential Companion Diagnostic
Investors in Myriad Genetics, Inc. saw new options become available this week, for the August 2018 expiration.
Demonstrates that EndoPredict Predicts Response to Neoadjuvant Therapy in HR+ Breast Cancer
